You are here: Industry Insights > ADC

News List

Piramal spends £55m to bolster its UK manufacturing presence CPhIonline
February 10, 2022
The investment covers two expansions to accommodate several pipeline products moving to commercial scale.
Piramal Pharma Solutions Expands & Upgrades UK Facilities contractpharma
February 08, 2022
£55 million investment includes a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth and enhanced API manufacturing in Morpeth.
Mersana, Janssen Biotech partner to discover new ADC product candidates pharmaceutical-business-review
February 04, 2022
Mersana Therapeutics and Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a research...
CuriRx Launches the Advanced Bioprocessing and Analytical Center contractpharma
January 26, 2022
New center allows the CDMO to further support biotherapeutic drug developers.
CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration prnasia
January 04, 2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies...
Genmab Gains Broad Access to Synaffix's ADC Technologies contractpharma
January 04, 2022
Secures rights for conducting research on ADCs against multiple drug targets under new licensing agreement.
Emergence Therapeutics Closes €87 Million Series A Financing Round contractpharma
December 08, 2021
Plans to advance its Nectin-4 antibody drug conjugate.
Abzena, BiVictriX Therapeutics Collaborate to Manufacture ADCs ContractPharma
November 19, 2021
BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience...
SOTIO, LegoChem Biosciences Enter ADC License Agreement ContractPharma
November 17, 2021
SOTIO Biotech, a clinical stage immuno-oncology company, entered an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc., a biotechnology company...
SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences B3Cnewswire
November 17, 2021
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc...

Previous page 1 2 3 4 5 6 7 8 9 10 Next page